ANIKA THERAPEUTICS, INC.

(ANIK)
  Report
Real-time Estimate Cboe BZX  -  05/16 02:38:49 pm EDT
22.31 USD   +0.11%
05/13Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
05/09Anika to Participate in the UBS Global Healthcare Conference 2022
AQ
05/06ANIKA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Stephens Starts Anika Therapeutics at Overweight With $55 Price Target

11/16/2021 | 05:23am EDT


© MT Newswires 2021
All news about ANIKA THERAPEUTICS, INC.
05/13Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
05/09Anika to Participate in the UBS Global Healthcare Conference 2022
AQ
05/06ANIKA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
05/05TRANSCRIPT : Anika Therapeutics, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05ANIKA : Q1 Earnings Snapshot
AQ
05/05Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q1 Loss $-0.11
MT
05/05Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 Revenue $36.7M, vs. Street Est of $..
MT
05/05Anika Reports First Quarter Fiscal 2022 Financial Results
AQ
05/05Anika Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/05Anika Therapeutics, Inc. Provides Revenue Guidance for the Year 2022
CI
More news
Analyst Recommendations on ANIKA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 154 M - -
Net income 2022 -11,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -29,4x
Yield 2022 -
Capitalization 324 M 324 M -
Capi. / Sales 2022 2,10x
Capi. / Sales 2023 1,90x
Nbr of Employees 297
Free-Float 98,2%
Chart ANIKA THERAPEUTICS, INC.
Duration : Period :
Anika Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANIKA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 22,28 $
Average target price 37,50 $
Spread / Average Target 68,3%
EPS Revisions
Managers and Directors
Cheryl Renee Blanchard President, Chief Executive Officer & Director
Michael L. Levitz Chief Financial Officer, Treasurer & EVP
Jeffery S. Thompson Chairman
Mira Leiwant VP-Quality, Regulatory & Clinical Affairs
Steven W. Ek Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ANIKA THERAPEUTICS, INC.-37.82%324
CSL LIMITED-3.62%93 394
SAMSUNG BIOLOGICS CO.,LTD.-14.73%43 585
BIOGEN INC.-17.01%29 160
WUXI BIOLOGICS (CAYMAN) INC.-43.92%27 891
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-22.41%23 276